Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3140 - Resected malignant melanoma at high risk of recurrence in SEER-Medicare

Date

10 Sep 2017

Session

Poster display session

Presenters

Natalia Sadetsky

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

N. Sadetsky1, J. Yi2, A. Hernandez1, D. Colburn1, G. Goodman1

Author affiliations

  • 1 Product Development, Genentech, Inc., 94080 - South San Francisco/US
  • 2 Epidemiology/analysis, Genesis Research Group, 07030 - Hoboken/US
More

Resources

Abstract 3140

Background

While surgery remains a mainstay in the management of high-risk resectable malignant melanoma (MM), there is a high chance of recurrence. Utilization of approved adjuvant therapies (e.g. interferon α and ipilimumab) are limited by the common occurrence of debilitating side effects. The objective of our study was to describe characteristics of patients (pts) with resected MM at high risk of recurrence in the older US population.

Methods

A retrospective cohort study was undertaken using the Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based linked database. The study population included pts with Stage IIC-IIIC surgically resected MM diagnosed between 2004 and 2011. Demographic and clinical characteristics, adjuvant therapies, including radiation (XRT) and/or systemic therapy (eg, interferon α, interleukin, pegylated interferon), and overall survival (OS) were evaluated.

Results

We identified 1016 pts; the mean age was 75.2 years (interquartile range [IQR], 72–82) and 66.2% were males. The majority of pts had Stage IIC-IIIB disease at diagnosis (Cohort 1; n = 877 [86.3%]); the remainder had stage IIIC disease (Cohort 2; n = 139 [13.7%]). Adjuvant therapy was utilized in 27.3% (n = 239) and 43.2% (n = 60) of pts in Cohorts 1 and 2, respectively, and consisted of XRT in 74% and 78% of pts, systemic therapy in 16% and 10% of pts (with interferon α representing 98.6% of systemic therapies), and a combination of XRT and systemic therapy in 10% and 12% of pts. OS differed between cohorts, with a median of 32.3 months (IQR, 17.9–53.3) for Cohort 1 and 19.8 months (IQR, 11.5–36.2) for Cohort 2. Landmark OS at 5 years was 20.8% for Cohort 1 and 12.2% for Cohort 2.

Conclusions

Among pts with resected MM at high risk of recurrence in the older US population, utilization of adjuvant therapy and OS varied based on disease stage at diagnosis. Pts with Stage IIIC disease were exposed to more medical interventions; however, use of highly toxic systemic therapy available during the study period was limited in both cohorts. As more therapies for the adjuvant setting are being developed, the evaluation of clinical and demographic characteristics may help tailor treatment regimens.

Clinical trial identification

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

N. Sadetsky, A. Hernandez, D. Colburn: Employee, Genentech, Inc. G. Goodman: Employee, Genentech, Inc.; owns stock in Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.